SpringerPlus

Table 3 Objective response rate in cases administered gefitinib 250 mg/day and dose redused due to liver damage

From: Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patients

	Skin rash
	+	-	Total
RECIST
CR	2	0	2
PR	8	3	11
SD	0	4	4
PD	0	7	7
CR + PR (%)	10 (100)	3 (21.4)	13 (54.2)

RECIST Response Evaluation Criteria in Solid Tumors, CR Complete Response, PR Partial Response, SD Stable Disease, PD Progressive Disease.

Back to article page